Gilead Loses Patent Case Over Lexiscan Generic
Gilead lost its bid to shield its Lexiscan brand of cardiac stress agent from generic competition by Pfizer when the top federal judge in Delaware ruled the new drug wouldn't actually...To view the full article, register now.
Already a subscriber? Click here to view full article